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Clinical pharmacology/research has a very interesting history. It started in the 40's of 
the 20th century through the pioneering work of Harry Gold at Cornell University, New 
York. Clinical research is an integral part of drug development. Drug development can 
be hastened by a number of new techniques with reduction in cost. In addition reverse 
pharmacology approaches for drug discovery have come to occupy a special place. 
85% of the neutral antagonists act as inverse agonists. Inverse agonists have a distinct 
effect on receptor regulation as opposed to neutral antagonists.
Orphan receptors constitute about 50% of the GPCRs. It is estimated that now there are 
nearly 175 orphan receptors after 125 having been deorphanised. Targeting these 
orphan receptors can lead to about the same number of ligands and antagonists thereof. 
Polymorphism of cytochrome P450 provides the basis for the use of predictive 
pharmacogenomics to yield drug therapies that are more efficient and safer. It is 
estimated that such personalized P450 gene-based treatment would be relevant for 10-
20% of all drug therapy.
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Strategies for drug discovery – Deorphanisation of orphan receptors, allosteric receptor 
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Prologue :
 Experimental pharmacology in 
India dates back to Col. Sir Ram Nath 
Chopra* who was trained with Dixon in 
Cambridge where he imbibed the gospel 
of providing experimental proof of the 
claimed therapeutic efficacy of any new 
product.  After a decade of return to India, 
he set up experimental pharmacology 
laboratory at the Tropical School of 
Medicine in Calcutta to give scientific 
basis for therapeutic claim made for many 
herbals in Ayurveda.  He investigated a 
large number of plants experimentally and 
his researches culminated in several 
publications.  In view of his pioneering 
work, he is rightly called the Father of 
Pharmacology in India (1).  
 His researches are the forerunner 
of subsequent experimental work in 
medical and pharmacy colleges and 
research institutes in India.  This led to the 
training of a large manpower equipped to 
chair the departments of pharmacology.  
 Unfortunately, the country has not 
been able to contribute the introduction of 
n e w  d r u g s  i n  t h e  t h e r a p e u t i c  
armamentarium of human disease. This is 
largely due to the fact that inputs involved 
in such endeavour in terms of time and 
money are mind boggling – the former 
about 10 years and the latter over 10 
billion US dollars.  Newer strategies 
involving pooling of resources by 
enterprising pharmaceutical companies 
may hopefully lead to realisation of this 
dream.
 An additional focus in this paper is 
to use approaches that can yield new drugs 
with fraction of the cost.  Thus, mining of 
the orphan receptor for drug discovery has 
already yielded a large number of new 
drugs (Table 1) with fraction of the cost.  
Similarly, computer simulation can also 
contribute new drugs with minimal 
financial inputs.
 Of my bibliographic profile 
totalling about 138 publications, 23(from 
Medical College and SSG Hospital, 
Baroda) are in clinical research work done 
in collaboration with  faculty of medicine 
(C.P.Munshi, P.M.Vaidya, B.T.Dave, 
K.M.Shah), faculty of pediatrics (Sanat 
Shah )  f acu l t y  o f  de rma to logy,  
venereology and leprology (B.S.Verma, 
V.P.Vaishnav and B.G.Byakod) and 
faculty of obstetrics and gynecology. 
(L.V.Kelkar, V.V.Kelkar, T.V.Patel).  
Past :
 Gregory  (1753-1821)  has  
described the symptomatic heroic 
treatment of the time, consisting of blood 
letting, emesis and purgatives which were 
prescribed until the disappearance of 
morbid phenomena (i.e.symptoms and 
* Col. Ram Nath Chopra was conferred Honorary Fellowship of the National Academy of 
Medical Sciences in 1961 : the other Honorary Fellowship awarded in 1961 (Foundation 
Year of the Academy) included Shri Jawahar Lal Nehru, Dr. B.C. Roy, Major Gen. S.L. 
Bhatia, Dr. H.M. Lazarus, Dr. Jivaraj N. Mehta, Dr. A. Lakshamanswami Mudaliar, Dr. 
N.A. Purandare, Major Gen. S.S. Sokey, and Dr. A.C. Ukil           (Editor)
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signs).  Very often there ensued rapidly a 
syncope, followed by death in such a way 
that the saying of this period, that the 
“patient is dead cured” was justifiably apt 
(1).  Voltaire (1694-1776) was prompted 
to define therapeutics as the art of pouring 
drugs of which we know little into man of 
whom we know still less.  In a similar vein 
Oliver Wendell Holmes (1809-1894) said 
“if all the materia medica (except, 
morphine) is sunk into the bottom of sea, it 
will be all the good for mankind and all the 
worse for fishes.”  These nihilistic 
dogmas of the time were pronounced by 
the prevalent despondency engendered by 
allopathy (a misnomer).  Homeopathy 
originated as a reaction to this.  In two 
recent articles published from UK, 
Homeopathy provides no more than 
placebo effect in the drugs prescribed by 
Homeopathic physicians (2,3).  The 
scenario today is starkly opposite and 
fortunately we have new potent vaccines, 
antiinfectives, psychotherapeutics and 
several other drugs that have helped save 
million of lives (4). 
 After the experimental evaluation 
of drugs in animals, it is necessary to 
investigate drugs in human beings – 
Clinical Pharmacology. The credit for 
pioneering this must go to Harry Gold of 
Cornell University Medical School. Gold 
et al (5) were the first to bioassay digitalis 
in humans. I had the good fortune of 
meeting both Harry Gold and Walter 
Modell in September 1959.  I was thrilled 
to watch Harry Gold performing his 
isolated tissue experiment. Walter Modell 
of the same institution continued the work 
initiated by Gold and a journal of Clinical 
Pharmacology was started. 
 U.K.Sheth is considered as the 
pioneer of clinical pharmacology in India.
 Outstanding are the experiments 
of S.M.Smith in Salt Lake City (Smith et 
al, 1947) who received, while conscious 
and on artificial respiration, around three 
otherwise lethal doses of curare, to test 
whether it affected the brain; or J.B.S. 
Haldane, who, to make diving safer, had 
bends, oxygen convulsions and nitrogen 
narcosis; or the Professor E.A.Pask, who, 
to test a safety kit for the RAF which might 
be needed to protect an unconscious 
bailed-out pilot from drowning, had 
himself anaesthetized, curarized, and 
thrown wearing the kit into a swimming 
bath.    These are all the outstanding 
pioneering examples of clinical research 
(6).
Present :
 Clinical pharmacology, a facet of 
clinical research, is organized on human 
beings intended to provide adequate 
information on the drug use as a 
therapeutic agent for its safety and 
efficacy. 
 We need clinical trials for new 
drug discovery, new uses of existing 
drugs, new drug delivery systems and 
medical devices. Furthermore, clinical 
trials are also intended to get evidence to 
prove the efficacy of a given drug and 
safety in human beings. Only a well 
designed clinical study on a defined 
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population can give meaningful results- 
(positive or negative) about any 
therapeutic intervention (7). 
Ethical Issues and Guidelines :
 The concept of Ethics was 
developed in the 20th century with the 
growth of pharma industry.  During 2nd 
world war, the Nazi physicians 
dehumanized Prisoners of War (POWs) 
during their clinical trials.  The 
Nuremberg code and informed consent 
came as welcome steps. World Medical 
Association (WMA)-1964-guidance to 
physicians and other participants in 
medical research involving human 
subjects further streamlined the ethical 
requirements. Thalidomide disaster 
brought about an exponential growth in 
Pharmaceutical legislation
 During 1950s proper testing of 
drugs on human beings was started. The 
concept of randomized controlled clinical 
trials was emphasized. 
 Several regulatory guidelines are 
available today. These include Drugs and 
Cosmetics Act 1947, Schedule-Y, Indian 
GCP Guidelines, ICMR Guidelines, 
WHO Guidel ines and ICH-GCP 
Guidelines.
 Other ethical issues and guidelines 
include those set forth by International 
Conference on Harmonization (ICH), 
Institutional Ethics Committee (IEC), 
Institutional Review Board (IRB) 
Good Clinical Practice (GCP) :
 It is the international standard for 
conducting clinical trials which lays down 
standard for design, conduct, monitoring, 
termination, analysis and documentation.  
 Informed consent is a written 
consent of a subject (in his own language) 
to participate in a trial.
Regulatory Requirements :
 F o r  f u l f i l l i n g  r e g u l a t o r y  
requirements, inputs from the following 
may be needed depending on national 
norms:
 Drugs and Cosmetics Act, Schedule-Y, 
 Drug Controller General of India 
(DCGI),
 United States Food and Drug 
Administration (USFDA) Act
 Medicinal and Health Care Products 
Regulatory Agency (MHRA)
Monitoring and Audit :
 Monitoring is usually conducted 
by research associates and involves 
overseeing the progress of a clinical trial 
and ensuring that it is conducted 
according to the protocol, GCP, Standard 
Operating Procedure (SOPs) and the 
regulatory requirements. Audit is 
conducted during monitoring to 
systematically and independently 
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examine the trial related documents and 
activities. It also checks whether the trial 
is going on as per the protocol, GCP, SOP 
and whether it is recorded and reported 
accurately or not.
Bioavailability and Bioequivalence 
studies :
 The former is done to understand 
how much of the drug is available for 
action; the latter is conducted for new 
formulations and compares new 
formulations of any established drug with 
the existing formulation. 
Biostatistics :
 Biostatistics is required during the 
protocol designing to calculate the 
number of patients to be included in the 
trial (sample size), randomization, to 
review the data and for the final analysis 
of results by applying suitable statistical 
methods.
Clinical Research 50 Years Ago and 
Now :
 Clinical research 50 years ago was 
investigator driven informal activity. 
Clinical research now is multi-
disciplinary, multinational, multibillion 
dollar global business governed by many 
complex and interrelated regulations and 
guidelines.   The players in this multi-
disciplinary approach include, pharma 
companies, biotech companies, Central 
Diagnostic Laboratories, Clinical 
Research Training Institutes, sponsors, 
investigators, monitors, auditors and 
qua l i t y  con t ro l  pe r s onne l ,  b io  
statisticians, data management groups, 
regulatory affairs, reporting and 
documentation – medical writing and 
business development groups.
Preclinical Studies :
 Preclinical studies are conducted 
on experimental animals for safety and 
efficacy.  Efficacy studies are done by in-
vitro assays using only animal tissues or 
cells or enzyme systems and in-vivo 
assays by experiments using whole 
animals. 
 Toxicity studies are done in 
animals and include acute toxicity studies 
– LD50, subacute toxicity studies, chronic 
toxicity studies, special toxicity studies – 
ca rc inogen ic i ty,  t e r a togenec i ty,  
genotoxicity and effects on fertility and 
reproduction.
Clinical Trial Phases :
 Phase-I- Clinical pharmacology, safety 
of new drugs 
 Phase-II-safety and efficacy of new 
drug in patients, exploratory trial.
 Phase-III- multicentric confirmatory 
trial. 
 Phase-IV-post- marketing surveillance
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Future:
Pharmacovigilance  :
 Pharmacovigilance is phase 4 
clinical trial and is intended to unmask 
uncommon side effects and new 
serendipitous beneficial effects and has to 
be multicentric ongoing process. It is also 
necessary for coordination between 
different centers and this is a hallmark of 
the program.
Pharmacoepidemiology (Populational 
Pharmacology) :
 Pharmacoepidemiology develops 
the following types of study:
i. Studies of drug effectiveness on 
large populations monitored during 
long-term periods
ii. Studies of adverse drug reactions 
with quantification of risk 
iii. Drug utilization studies to asses the 
characteristics of drug prescription 
or consumption according to 
evidence based data or official 
guidelines. 
iv. These studies also investigate 
differences in drug prescriptions 
according to national or regional 
habits, characteristics of the patients 
and physicians, among others.
v. Finally, pharmacoepidemiology 
asks the most important question 
with respect to drugs: what are we 
doing in clinical practice with the 
basic properties of drugs? 
Dictionary of Pharmacoepidemiology 
gives detailed study of this topic (8).
Drug Discovery :
Role of Modern Techniques in Drug 
Discovery:
 Mode rn  day  advances  i n  
medicinal chemistry (combinatorial 
library synthesis), molecular biology 
( r e c o m b i n a n t  D N A - t e c h n o l o g y,  
transgenic animal models, knock-out 
mice and human gene sequencing), 
informat ion technology (chemi-
informatics and bio-informatics), 
screening sciences (ultra high throughput 
and automation miniaturization, nuclear 
magnetic   resonance imaging and 
positron emission tomography – PET) 
h a v e  g r e a t l y  i m p a c t e d  t h e  
pharmacologist's approach to studying 
and identifying novel targets. They have 
led to strengthening of forward and 
reverse pharmacology (Figure 1). 
Through these tools the pharmacolgist 
places potential drugs at the disposal of 
the clinical pharmacologist at a much 
rapid pace- Table 1 (9).
Drawbacks :
 Although data can be generated at 
an extremely fast pace, the pace of 
analysis cannot cope up with the rate of 
generation of data.
Table 1 (9) : Using reverse pharmacology to identify novel receptor – ligand 
interactions with potential cardiovascular applications*
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Forward Pharmacology Reverse molecular pharmacology 
functional activity bioinformatics/molecular genetics 
ligand purification full length cloning 
 
ligand receptor 
functional studies ligand fishing 
  
biological role/pathophysiology ligand 
  
receptor fishing receptor/ligand 
receptor compound screening 
receptor/ligand functional studies 
(compound+ligand) 
compound screening biological role/pathophysiology 
  
medicinal chemistry medicinal chemistry  
clinical development clinical development 
FIGURE 1 : Paradigm shift from forward pharmacology to reverse molecular 
pharmacological approaches for drug discovery.
Orphan receptor Cognate ligand 
Putative cardiovascular 
actions
 
Potential indications
UT 
(GPR14,SENR)
 
Urotensin-II
 
Vasoconstriction, cardiac 
inotropy
 
Hypertension, heart 
failure 
 
Mas
 
Angiotensin-(1-7)
 
Vasorelaxation,anti -
diuretic
 
Hypertension, heart 
failure
 
GPR66(TGR1,FM
3)
Neuromedin U
 
Vasoconstriction,cardiac 
inotropy
 
Hypertension, heart 
failure
 
* Abbreviations: BP, blood pressure; EC, endothelial cell; i.c.v. intracerebroventricular; MAPK, 
mitogen-activated protein kinase; PLC, phospholipase C; SNP, single nucleotide polymorphism.
** RF-amide, a family of neuropeptides that are characterized by the Arg-Phe-amide motif.  
The prototypic isotype is Phe-Met-Arg-Phe-amide (FMRF-amide).
TA 
Trace 
amines(tyramine) 
Vasoconstriction  Hypertension  
GPR38 Motilin Vasodilatation(indirect)  Hypertension  
GHS-R Ghrelin  Vasodilatation  Heart failure  
LGR7,8
 
Relaxin
 
Cardiac inotrope, 
vasodilatation
 
Heart failure
 
CRF1/2
 
Urocortin
 
Vasodilatation
 
Heart failure
 
edg-1(LPB1)
 
Sphingosine-1-
phosphate
 
EC differentiation, PLC 
and MAPK activation
 
Athero-thrombosis, 
angiogenesis
 
edg-2,4,7(LP A1-3)
 
Lysophosphatidic 
acid
 
DNA synthesis, PLC and 
MAPK activation
 
Athero-thrombosis.
G2A
 
Lysophosphatidylc
holine
 
Macrophage function
 
Athero-thrombosis
 
P2Y12 (SP1999)
 
ADP
 
Platelet aggregation
 
Thrombosis
 
HM74/-A
 
Nicotinic acid
 
Lipid lowering, anti-
lipolytic
 
Atherosclerosis,dysli
pidemia
 GPR40
 
Medium-chain fatty 
acids
 
Insulin regulation
 
Syndrome X
 AdipoR1,R2 Adiponectin Fatty acid metabolism Syndrome X
APJ
 
Apelin
 
Vasoconstriction,cardiac 
inotropy
 Hypertension, heart 
failure
 
PTH2
 
TIP-39
 
Vasodilatation (renal)
 
Hypertension, heart 
failure
 
GPR10(GR3,UHR
-1)
 Prolactin releasing 
peptide
 BP regulation (SNP 
phenotype)
 Hypertension
 
OXR (HFGAN72)
 
Orexin A,B
 BP regulation (i.c.v. 
administration)
 Hypertension
 
GPR103(HLWAR
77) 
RF-amides
** BP regulation (i.c.v. 
administration)  
Hypertension  
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G-Prote in  Coupled  Receptors  
(GPCRs):
 The receptor theory of drug action 
traces its origin to the work of Ehrlich 
(10), Langley (11), and Clark (12), who 
are credited with being the originators of 
receptor theory. In general classical theory 
evolved chronologically through concepts 
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Agonism, Inverse Agonism and Neutral 
Antagonism :
 Several mutations result in 
enhanced constitutive activity leading to 
inherited human diseases such as adreno-
corticotropin resistance and hypocalciuric 
hypercalcemia. Significant activity of 
these receptors can be detected in the 
absence of agonists. 
 Some drugs which had been 
considered as  antagonis ts  were  
subsequently found to reduce this activity. 
These drugs were assigned negative 
values of intrinsic activity – inverse 
further developed by Stephenson, Ariens, 
Furchgott, Gaddum, and Schild (13).
 The past 25 years have witnessed a 
renaissance in receptor theory. GPCRs are 
now seen as interactive, information 
processing units beyond switches for G 
proteins (Figure 2) (14).
 It is estimated that some 45-60% 
of the drug entities in any modern day 
pharmacopoeia exert their actions either 
directly or indirectly via GPCRs. GPCR 
(14) is now considered the jewel of 
pharmacology. 
FIGURE 2 : Transmembrane topology of a typical serpentine receptor. :  The 
receptor's amino (N) terminal is extra cellular (above the plane of the membrane), and its 
carboxyl ( C ) terminal intracellular.  The terminals are connected by a polypeptide chain 
that traverses the plane of the membrane seven times.  The hydrophobic transmembrane 
segments (light colour) are designated by Roman numerals (I-VII).  The agonist (Ag) 
approaches the receptor from the extracellular fluid and binds to a site surrounded by the 
transmembrane regions of the receptor protein.  G proteins (G) interact with cytoplasmic 
regions of the receptor, especially with portions of the third cytoplasmic loop between 
transmembrane regions V and VI.  The receptor's cytoplasmic terminal tail contains 
numerous serine and threonine residues whose hydroxyl (-OH) groups can be 
phosphorylated.  This phosphorylation may be associated with diminished receptor-G 
protein interaction. 
25Clinical Research - Past, Present & Future
agonists. These drugs have different 
pharmacological potential from that of 
neutral antagonists. It is likely that inverse 
agonists will have a distinct effect on 
receptor regulation. 
 Full agonism and full inverse 
agonism constitute the extreme endpoints 
of a continuum that characterizes the 
functional properties of orthosteric 
ligands – conformational model. In this 
model the receptor constantly oscillates 
b e t w e e n  a c t i v e  a n d  i n a c t i v e  
conformations. Agonists bind with high 
affinity to active conformation, which 
they stabilize whereas inverse agonists 
stabilize an inactive conformation. In fact 
85% of competitive antagonists are 
inverse agonists. 
 Neutral antagonist is competing 
ligand that does not discriminate between 
active and inactive conformation. Thus 
the antagonists on their own do not favor 
any of the   conformations of the receptor, 
but have the capacity to interfere with the 
other ligands.
 Clearly, the use of inverse agonist 
that stabilizes the inactive conformation 
instead of neutral antagonist is preferable 
for the treatment of human diseases 
associated with GPCR – activating 
mutations. Several native receptors such 
as 5HT1A, 5HT2A and 5HT2C (5-
h y d r o x y t r e c t o m y )  r e c e p t o r s ,  
melanocortin receptors and histamine H3 
receptors show noticeable constitutive 
activities in physiological conditions 
suggesting that inverse agonists have 
great potential as inverse agonists
Orphan Receptors :
 Of the 10000 – 30000 genes 
encoded by human genome, 600-1000 are 
estimated to be GPCRs, 30% are non 
sensory (olfactory and gustatory) 50% of 
this group are orphan receptors - presently 
the ligands are not defined for about 175 
(15,16).
 The pharmaceutical industry has 
recognized the power of genomics to 
provide it with new unique drug targets 
including over 100 GPCRs to a wide 
variety of human diseases and the 
historical sources of drugs that target 
GPCR –Table 1 (9). Thus, progress in 
fostering orphan GPCR by mining human 
genome has been impressive over the last 
two years and resulted in identification of 
numerous novel molecular targets  
(Figure 3) (17). 
Methods to target orphan receptors : 
(18)
1. Mining of the human genome.
2. Advances in quantification of tissue 
and disease – specific gene 
expression
3. Receptor – ligand pairing to find 
cognate ligand for an orphan 
receptor is identified by screening 
panels of known GPCR ligands 
from tissue extracts
 This is a potential area that can yield 
about 175 agonists & 175 antagonists 
(15,19) with about 80% as inverse 
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FIGURE 3 : Strategy for using orphan G protein-coupled receptors as targets 
for drug discovery.
bioinformatics
expression pattern
full-length cloning
receptor expression
ligand
screens for
antagonist/agonist
functional assays
2+
cAMP, Ca
biology/pharmacology
drug discovery
antagonist/agonist
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agonists. Some of the competitive 
antagonists could also be inverse agonists
Drug Discovery through Receptor 
Conformation Theory: 
 The past decade has witnessed a 
dramatic increase in the identification of 
allosteric modulators of G-protein-
coupled receptor (GPCR) activity. 
Concomitantly, several new perspectives 
and hypotheses regarding the way ligands 
regulate GPCR signaling have also 
emerged. The concepts of collateral 
efficacy and permissive agonism-
antagonism intersect the field of allosteric 
GPCR modulation. Despite the challenges 
associated with detecting and quantifying 
the myriad of possible allosteric effects on 
GPCR activity, it is proposed that 
allosteric ligands offer the exciting 
prospect of engendering stimulus-bias in 
orthosteric ligand signaling, thus paving 
the way for not only receptor-selective but 
also s ignal ing-pathway-select ive 
therapies. Examples: Beta-blockers, 
Metabotropic glutamate receptor 
activation (20).
Personalized Therapy :
 The field of cytochrome P450 
pharmacogenetics has progressed rapidly 
during the past 25 years. All the major 
human drug-metabolizing P450 enzymes 
have been identified and cloned, and the 
major gene variants that cause inter-
individual variability in drug response and 
are related to adverse drug reactions have 
been identified. This information now 
provides the basis for the use of predictive 
pharmacogenetics to yield drug therapies 
that are more efficient and safer. Today, 
we understand which drugs warrant 
dosing based on pharmacogenetics to 
improve drug treatment and increasing the 
efficacy of drugs and health in general. It 
is estimated that such personalized P450 
gene-based treatment would be relevant 
for 10-20% of all drug therapy (21).
 Computational Neuropharmacology :
 A promising and innovative 
discipline named as computational 
neuropharmacology as summarized 
below has emerged.  This discipline 
which combines s ta te-of- the-ar t  
computational techniques established in 
basic neurosciences with traditional 
neuropharmacological methods could 
open new vistas in drug discovery that 
might help the development of new 
the rap ies  fo r  neuro log ica l  and  
psychological disorder.  The kinetic 
analysis of modulatory effect on the 
interaction of gamma amino butyric acid 
(GABA) transmitter and GABAA  
receptor which alters septo-hippocample 
rhythmic activity to screen and design 
putative subunit  dependent selective 
anxiolytics  (drugs to relieve anxiety).  
Secondly, the dynamic sub-cellular and 
network activity in epilepsy are described 
in the context of finding new targets and 
methods for seizure control (22).
Summary :
 Clinical research has a very 
interesting history. It started about 50 
years ago. Clinical research is an integral 
part of drug development. 
 Clinical pharmacology started in 
the 40's of the 20th century through the 
pioneering work of Harry Gold at Cornell 
University New York. Clinical research is 
an integral part of drug development. 
Unlike the past, today the process has 
gained a unique position due to the 
regulatory requirements and ethical 
guidelines available globally. Designing, 
conducting, monitoring, appropriate 
quality assurance and data management 
determine the success of the clinical 
research. Pharmacovigilance and 
pharmacoepidemiology are now gaining 
importance since without these no clinical 
pharmacology work can be complete.
 Drug discovery can be hastened 
by a number of new techniques with 
reduction in cost. In addition reverse 
pharmacology approaches for drug 
discovery have come to occupy a special 
place. There is only one drawback i.e. the 
pace of analysis of data cannot cope up 
with the rate of generation of new data. 
85% of the neutral antagonists act as 
inverse agonists. Inverse agonists have a 
distinct effect on receptor regulation as 
opposed to neutral antagonists.
 Orphan receptors constitute about 
50% of the GPCRs. It is estimated that 
now there are nearly 175 orphan receptors 
after 125 having been deorphanised. 
Targeting these orphan receptors can lead 
to the same number of ligands and 
antagonists thereof. Polymorphism of 
cytochrome P450 provides the basis for 
the use of predictive pharmacogenomics 
to yield drug therapies that are more 
efficient and safer. Such personalized 
P450 gene-based treatment would be 
relevant for 10-20% of all drug therapy. 
Allosteric conformation of receptors and 
in-silico technology could provide other 
inputs for drug discovery.
 Orphan receptors, conformation 
of receptors, polymorphism of P450 and 
insilico discovery are new challenges that 
can yield new inputs for clinical research. 
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